EP3641762A1 — N/o-linked degrons and degronimers for protein degradation
Assigned to C4 Therapeutics Inc · Expires 2020-04-29 · 6y expired
What this patent protects
The present invention relates to degronimers that include fragments targeting ubiquitin E3 ligase (Degons), which may be linked to a targeting ligand of a protein that has been selected for in vivo degradation, methods of use, and compositions. containing them as well as methods …
USPTO Abstract
The present invention relates to degronimers that include fragments targeting ubiquitin E3 ligase (Degons), which may be linked to a targeting ligand of a protein that has been selected for in vivo degradation, methods of use, and compositions. containing them as well as methods for preparing them. The invention also relates to cleavage agents that can be used to treat cereblon-mediated disorders or a protein of the Ikaros family, and methods of use and compositions thereof as well as methods for their preparation.
Drugs covered by this patent
- Zepatier (ELBASVIR) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.